Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-5269
Zaïr, Z M; Eloranta, J J; Stieger, B; Kullak-Ublick, G A (2008). Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics, 9(5):597-624.
|Accepted Version (Creative Commons: Attribution 3.0 Unported
PDF - Registered users only
The role of carrier-mediated transport in determining the pharmacokinetics of drugs has become increasingly evident with the discovery of genetic variants that affect expression and/or function of a given drug transporter. Drug transporters are expressed at numerous epithelial barriers, such as intestinal epithelial cells, hepatocytes, renal tubular cells and at the blood-brain barrier. Several recent studies have associated alterations in substrate uptake with the presence of SNPs. Here, we summarize the current knowledge on the functional and phenotypic consequences of genetic variation in intestinally, hepatically and renally expressed members of the organic anion-transporting polypeptide family (OATPs; SLC21/SLCO family), the organic anion and organic cation transporters (OATs/OCTs; SLC22 family) and the peptide transporter-1 (PEPT1; SLC15 family).
|Item Type:||Journal Article, refereed, further contribution|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Clinical Pharmacology and Toxicology
04 Faculty of Medicine > Center for Integrative Human Physiology
|DDC:||570 Life sciences; biology
610 Medicine & health
|Deposited On:||01 Dec 2008 11:36|
|Last Modified:||27 Nov 2013 21:06|
|Citations:||Web of Science®. Times Cited: 50|
Scopus®. Citation Count: 60
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page